Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 17/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.41 |
| ▸ | FAP | Q12884 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18401046 | 0.98 | DPP4 (0.46) | DPP4EPHX1DPP7KCNH2DPP8 | |
| SCHEMBL20877709 | 0.98 | DPP4 (0.46) | DPP4EPHX1DPP7KCNH2DPP8 | |
| SCHEMBL22968844 | 0.98 | DPP4 (0.46) | DPP4EPHX1DPP7KCNH2DPP8 | |
| SCHEMBL12937984 | 0.89 | ALOX5 (0.40) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL14886200 | 0.89 | ALOX5 (0.40) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL10140621 | 0.89 | ALOX5 (0.40) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL24063542 | 0.80 | DPP4 (0.44) | DPP4EPHX1DPP7KCNH2DPP8 | |
| SCHEMBL8021388 | 0.80 | EPHX1 (0.41) | EPHX1CA12CA1CA2MMP2 | |
| SCHEMBL9251508 | 0.80 | EPHX1 (0.41) | EPHX1CA12CA1CA2MMP2 | |
| SCHEMBL8003564 | 0.80 | EPHX1 (0.41) | EPHX1CA12CA1CA2MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200339581-A1 | AMINO INDOLE COMPOUNDS USEFUL AS TLR INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-10-29 | — | — | US | disclosed |
| US-7728148-B2 | Acyclic oximyl hepatitis C protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-7728148-B2 | Acyclic oximyl hepatitis C protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| WO-2009094443-A1 | DIFLUORINATED TRIPEPTIDES AS HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009094438-A1 | HETEROARYL-CONTAINING TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009076166-A2 | OXIMYL HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009076173-A2 | FLUORINATED TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009073780-A1 | PROCESS FOR MAKING MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-06-11 | — | — | WO | disclosed |
| US-20080187516-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080187516-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080125444-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-05-29 | — | — | US | disclosed |
| US-20080125444-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-05-29 | — | — | US | disclosed |
| WO-2007146695-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007143694-A2 | MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125444-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | CPN1, HPN, HCCS | DPP4 12/4885EPHX1 410/4885DPP7 108/4885 |
| US-20200339581-A1 | AMINO INDOLE COMPOUNDS USEFUL AS TLR INHIBITORS | TLR7, TLR1, TLR9 | DPP4 2500/4885EPHX1 4165/4885DPP7 893/4885 |
| US-20080187516-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | CPN1, HPN, HCCS | DPP4 12/4885EPHX1 410/4885DPP7 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.